<DOC>
	<DOCNO>NCT01940315</DOCNO>
	<brief_summary>This Phase 3 clinical trial double blind , placebo-controlled , randomize , multicenter investigation rBV A/B male female healthy adult 18 55 year age .</brief_summary>
	<brief_title>Phase 3 , Randomized , Safety , Lot Consistency Clinical Benefit Study Recombinant Botulinum Vaccine A/B</brief_title>
	<detailed_description>Currently , license vaccine pre-exposure prophylactic medical countermeasure available provide protection botulism . The rBV A/B development provide protection adult 18 55 year age fatal botulism cause inhalational intoxication botulinum neurotoxin complex ( BoNT ) serotype A , subtype A1 ( BoNT/A1 ) botulinum neurotoxin complex serotype B , subtype B1 ( BoNT/B1 ) . Volunteers expose botulism . Protective antibody titer measure serum vaccination .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . The volunteer U.S. citizen permanent resident alien U.S. 2 . The volunteer sign informed consent form . 3 . The volunteer 18 55 year age . 4 . The volunteer agree donate blood blood product therapeutic research purpose . 5 . The volunteer willing comply requirement protocol last scheduled visit . 6 . The volunteer accessible telephone electronic mail receive reminder investigative site . 7 . Female volunteer childbearing potential must pregnant lactate agree use two type acceptable form FDAapproved contraception end study . 8 . The volunteer good health . 9 . The volunteer clinical laboratory test within acceptable range list protocol . 1 . The volunteer history botulism prior receipt botulinum vaccine , toxoid antitoxin . 2 . The volunteer previously treat expect treat therapeutic product contain BoNTs Botox® , Myobloc®/Neurobloc™ Botox® Cosmetic . 3 . The volunteer history hypersensitivity significant adverse reaction vaccine , aluminum compound yeast . 4 . The volunteer history severe allergic reaction anaphylaxis . 5 . The volunteer donate one unit blood ( ≥ 450 mL ) undergone plasmapheresis within past 28 day prior receive first administration study product . 6 . The volunteer receive blood product immunoglobulin previous 6 month prior receive first vaccination plan receive product clinical trial . 7 . The volunteer receive investigational vaccine previous 6 month . 8 . The volunteer receive intend receive license nonliving vaccine within 14 day schedule administration study product . 9 . The volunteer receive intend receive licensed live vaccine , include FluMist® within 60 day schedule administration study product . 10 . Vaccination commercially available inactivated nonliving influenza vaccine preparation ( FluMist® ) receive 14 day schedule administration study product . 11 . The volunteer receive investigational drug therapy within 30 day first vaccination last scheduled visit . 12 . The volunteer receive therapy immunosuppressive agent , include use moderate highdose oral inhale systemic corticosteroid ( prednisoneequivalent dose ≥ 20 mg/day ) . 13 . The volunteer develop medically diagnose chronic migraine headache ( persistent recurrent ) neurological condition associate cranial nerve spasticity abnormal muscle contraction , demyelination , abnormality smooth skeletal muscle function hyperhidrosis . 14 . The volunteer systemic recurrent disease condition would place volunteer unacceptable risk injury require frequent continuous medical intervention treatment , require hospitalization , likely require surgical intervention course study . 15 . The volunteer current active mental illness , history mental illness hospitalization mental illness within past 12 month prior first administration study product exclusionary . 16 . The volunteer history immunodeficiency autoimmune disease . 17 . The volunteer systemic medical condition ongoing require hospitalization administration antimicrobial agent within 6 month screen . 18 . The volunteer history active rheumatoid arthritis autoimmune mediate arthritis . 19 . The volunteer acute selflimited illness resolved time first vaccination include oral temperature great 99.5 °F . 20 . The volunteer history abuse alcohol drug within 12 month clinical trial screening . 21 . The volunteer occupational responsibility would prevent completion participation clinical trial opinion Investigator . 22 . The volunteer body mass index ( BMI ) ≥ 35 kg/m2 . 23 . The volunteer member team conduct clinical trial dependent relationship clinical trial investigator . 24 . The volunteer confirm positive result urine drug screen test common substance abuse amphetamine , barbiturate , benzodiazepine , cocaine , opiates cannabinoids . 25 . The volunteer seropositive screening test human HIV , Hepatitis C virus hepatitis B surface antigen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Defender Study</keyword>
	<keyword>experimental vaccine</keyword>
	<keyword>inhalational intoxication</keyword>
</DOC>